not exactly sitting passive.......
Monday August 27, 7:31 pm Eastern Time
Press Release
SOURCE: Coalition for Pulmonary Fibrosis
Scientific Advisory Board Formed to Further
Awareness of IPF
Nation's Leading Physicians and Researchers Named to Positions On
Coalition for Pulmonary Fibrosis' Scientific Advisory Board
SAN FRANCISCO, Aug. 27 /PRNewswire/ -- The Coalition for Pulmonary Fibrosis
(CPF) announced today the formation of its Scientific Advisory Board to provide counsel
and medical expertise for educational projects related to the definition, diagnosis, treatment
and research of idiopathic pulmonary fibrosis (IPF), a fatal lung disease with no current cure.
The Scientific Advisory Board is comprised of 13 of the nation's leading physicians,
researchers and medical professionals involved in the treatment and research of pulmonary
fibrosis, specifically IPF. Board members volunteer their services to the CPF, a new
organization dedicated to furthering the outreach efforts of patient advocacy groups, medical
organizations and institutions involved with IPF, and to improving understanding and
awareness of this deadly disease among physicians, patients and their families.
IPF is a progressive and often fatal lung disease that affects an estimated 50,000 Americans
and has no known cause or cure. It is characterized by a progressive scarring, or fibrosis,
and deterioration of the lungs to the point of eventual suffocation. IPF is difficult to diagnose
and an estimated two-thirds of patients die within five years of diagnosis.
``IPF is a devastating illness, yet there is little awareness and minimal research for this lung
disorder,'' said Talmadge E. King, M.D., vice chairman of the Department of Medicine at
University of California San Francisco, chief of Medical Services at San Francisco General
Hospital and chairman of the CPF's Scientific Advisory Board. ``The Coalition for
Pulmonary Fibrosis' Scientific Advisory Board was established to help provide scientifically
credible information on IPF to both the patient and physician communities.''
Additional charter members of the Scientific Advisory Board include Serpil C. Erzurum,
M.D., Cleveland Clinic Foundation; Adaani Frost, M.D., Baylor University; Gary W.
Hunninghake, M.D., University of Iowa; Kevin O. Leslie, M.D., Mayo Clinic Scottsdale;
James E. Loyd, M.D., Vanderbilt University Medical Center; Fernando J. Martinez, M.D., University of Michigan Medical
Center; Paul W. Noble, M.D., Yale University; Ganesh Raghu, M.D. University of Washington; David A. Schwartz, M.D.,
Duke University Medical Center; Cecelia M. Smith, D.O., University of California San Diego Medical Center; Robert M.
Strieter, M.D., University of California Los Angeles; Javier B. Szwarcberg, M.D., Washington University.
About the Coalition for Pulmonary Fibrosis
The Coalition for Pulmonary Fibrosis (CPF) is a nonprofit organization, founded in 2001 to further education, patient support
and research efforts for pulmonary fibrosis, specifically idiopathic pulmonary fibrosis. The CPF is governed by patients and
individuals affected by pulmonary fibrosis and idiopathic pulmonary fibrosis, the nation's leading pulmonologists, medical
research professionals and supporting nonprofit organizations. Based in San Francisco, Calif. the CPF is funded by an
unrestricted educational grant from InterMune, Inc. (Nasdaq: ITMN - news).
For more information, please visit the CPF Web site at www.coalitionforpf.org or call 415-486-3248.
SOURCE: Coalition for Pulmonary Fibrosis |
